News & Updates

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.

Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.

Each additional optimal modifiable factor among women with a history of gestational diabetes mellitus (GDM) significantly contributes to a reduction in type 2 diabetes (T2D) risk, suggests a recent study. These associations are also present among individuals who are overweight/obese or are at greater genetic susceptibility to T2D.

In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.

The ratio between gamma-glutamyl transferase (GGT) and high-density lipoprotein cholesterol (HDL-c) shares a positive and nonlinear relationship with incident diabetes, reports a recent Japan study.

PCSK9 inhibition with evolocumab produces clinically meaningful and sustained reductions in certain lipid parameters in a predominantly Arabic population of individuals with familial hypercholesterolaemia (FH) and other non-FH indications, according to a study.

An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.